Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Advanced-stage endometrial cancer often lacks effective treatment options, especially for recurrent cases.
• Current therapies, including platinum and paclitaxel chemotherapy, have limitations for advanced disease.
• There is a critical need for novel therapeutic strategies in advanced endometrial cancer.

Purpose of the Study:

• To evaluate the pre-clinical efficacy of Oklahoma Nitrone 007 (OKN-007) as a single agent and in combination with carboplatin and paclitaxel.
• To elucidate the mechanism of action of OKN-007 in endometrial cancer models.
• To assess OKN-007's impact on tumor growth, viability, and key molecular pathways.

Main Methods:

• Assessed metabolic viability and clonogenic growth of endometrial cancer cells in 2D and 3D cultures.
• Utilized an intraperitoneal xenograft model for in vivo efficacy evaluation.
• Performed targeted gene expression profiling to identify molecular mechanisms and altered pathways.

Main Results:

• Endometrial cancer cells demonstrated sensitivity to OKN-007 in both 2D and 3D cultures.
• OKN-007 significantly reduced 3D spheroid and clonogenic growth.
• OKN-007 downregulated indolamine 2,3-dioxygenase 1 (IDO1) and modulated inflammatory pathways (IFN-, Jak-STAT, TGF-β, NF-kB), downstream effectors (mTOR, AhR), and T-cell co-signaling.

Conclusions:

• OKN-007 effectively targets pro-inflammatory, immunosuppressive, and pro-tumorigenic pathways in endometrial cancer.
• OKN-007 demonstrates pre-clinical efficacy and a promising mechanism of action for endometrial cancer treatment.
• OKN-007 represents a potential new therapeutic strategy for advanced and recurrent endometrial cancer with minimal toxicity.